Chanelle Pharma has launched a second new AVM-GSL product Imidaflea, which is a generic imidacloprid treatment.
Imidaflea is fast-acting, killing fleas within 24 hours of treatment and preventing further flea infestations for up to four weeks in dogs and cats, and up to one week in rabbits. It is an Authorised Veterinary Medicine-General Sales List (AVM-GSL) product containing the same active ingredients as the brand leader, Advantage.
Imidaflea is Chanelle’s second product to join its new AVM-GSL range alongside Fipnil Plus (Fipnil S Methoprene). The products can be sold over the counter in pet shops and other retail outlets.
Abi Busk, head of retail for Chanelle Pharma, said: “We are delighted to launch our second AVM-GSL product into the market place increasing our offering available to pet shops and to further support pet owners throughout the UK.”
The product comes in a variety of pack sizes to cater for cats and different-sized dogs, each with three easy-to-use pipettes. One pipette is recommended every four weeks to offer lasting protection from fleas and lice.
Chanelle Pharma is Ireland’s largest manufacturer of generic medicines for human and animal health. It currently exports to 97 countries and supplies 10 of the top 12 human and animal health multinational companies globally.
